biomed devic servic
price close busi april
domin global leader next gener
sequenc instrument consum
deliv robust beat rais fy guid rais
pt growth lever intact
deliv top-lin beat rais fy guid mainli reflect
beat guid street driven broad spatter growth across
busi result led y/i growth sequenc consum record
microarray servic y/i q/q mainli ancestri com posit
read-through small cap buy-rat bull thesi squar intact
continu call must stock particularli large-cap growth mandat
remain top pick given domin leadership nascent next-gen
sequenc market plethora growth driver ahead buy rais pt
beat driven array consum rev y/i beat
our/street beat beat arrays/servic y/
beat consum y/i vs model driven robust
novaseq nextseq pull-through thank sequenc wg we liquid
biopsi adj ep crush driven
revenu beat benefit fx benefit one-tim tax benefit
relat recogn loss helix adj gm y/i beat
adj om beat
guid us/th street expect rev come modestli
q/q ahead prior expect
on-going growth sequenc consum partli off-set normal season step
microarray mainli dtc consum revenu
rais guid suggest visibl growth appear leav room anoth
rais year rais revenue guid
y/i guid adj ep
vs prior given beat guid guid
street rais guid suggest higher revenu
view small readili achiev given manag expect
grow consum microarray consumables/servic
holi array total services/oth rev y/i beat
array services/oth grew q/q record primarili due process
ancestri com sampl order holiday season microarray consum
also record y/i q/q primarili
dtc custom agrigenom ceo franci desouza indic compani
seq see strong util flow cell
expect seq shipment declin q/q longer provid quarterli
number howev see strong feedback new flow cell launch feb
reiter novaseq placement guid unit y/i
order came custom new sequenc bench-top system
model rais revenue estim y/i
rev y/i adj ep
y/i rais rev y/i growth
rais adj ep
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
move clinic applic includ immuno-oncolog
recent announc import new partnership bristol-my squibb bm
measur biomark includ tumor mutat burden tmb seek predict
whether patient respond immunotherapi checkpoint inhibitor
intend develop commerci distribut ivd support bmss
oncolog immunotherapi addit announc mid-april partnership
develop commerci multi-gen panel broad tumor profil result
distribut ngs-base companion diagnost pan-canc indic co-
develop partnership seek approv version trusight tumor
companion diagnost loxo oncolog larotrectinib target ntrk
gene fusion target ret gene alter across tumor type
announc consist object play leadership role
enabl sequenc oncolog applic support routin test immuno-
oncolog therapi select monitor
see robust double-digit growth globe major geograph
region revenu america grew y/i emea grew robust y/i asia
pacif grew y/i shipment greater china includ china taiwan hong
research novaseq convers schedul may
good thing durat growth novaseq adopt like
continu good pace least like longer view
 custom instal least one novaseq fulli convert
fleet instrument novaseq manag cite rational
cadenc clinic translat research activ end result
novaseq like multi-year adopt cycl least like
end longer view depend whether follow
anoth blockbust launch perhap
new custom novaseq manag state
novaseq order either new sequenc previous
benchtop custom new-to-illumina custom academ translat
lab clinic test whole exom sequenc we whole genom
sequenc wg convert desktop-onli we wg circul
tumor dna liquid biopsi work methyl analysi rna project
clinic oncolog test shipment grew y/i expect
segment continu solid growth nipt also continu grow
work harvard pilgrim show data highlight util averag risk nipt
test may facilit broader commerci payor averag risk nipt view
clear grow adopt average-risk nipt mark materi growth driver
next sever year whenev aet decid cover average-risk
women make birth year us
nextseqdx last novemb launch nextseq second
fda-clear system follow miseqdx system flexibl run either
diagnost mode research mode expect launch number clinic
applic oncolog reproduct health system time earli
custom look use system liquid biopsi test use non-smal cell
lung cancer nsclc addit clinic assay develop
stock price compani mention
buy unchang target price april
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
